Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. - Wikidata - awgldk - TriplyDB

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.

http://www.wikidata.org/entity/Q37469987

about

Aptamer-nanoparticle complexes as powerful diagnostic and therapeutic tools.Aptamers: A promising chemical antibody for cancer therapy Targeting Th17 Cells with Small Molecules and Small Interference RNA Cell Penetrating Peptide Conjugated Chitosan for Enhanced Delivery of Nucleic Acid Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity Nucleic acid aptamers: an emerging frontier in cancer therapy Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy From ugly duckling to swan: unexpected identification from cell-SELEX of an anti-Annexin A2 aptamer targeting tumors Aptamer-Mediated Targeted Delivery of Therapeutics: An Update Aptamers: A New Technological Platform in Cancer Immunotherapy Manipulating the in vivo immune response by targeted gene knockdown Current prospects for RNA interference-based therapies Progress toward in vivo use of siRNAs-II Aptamer-Drug Conjugates Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice RNA plasticity and selectivity applicable to therapeutics and novel biosensor development Inhibition of cell proliferation by an anti-EGFR aptamer Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles Generation of siRNA Nanosheets for Efficient RNA Interference Silencing disease genes in the laboratory and the clinic Aptamer in bioanalytical applications.In vivo imaging of RNA interference.Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.Direct validation of aptamers as powerful tools to image solid tumor Aptamer-targeted cell-specific RNA interference Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.How to train your dragon: targeted delivery of microRNA to cancer cells in vivo.A U87-EGFRvIII cell-specific aptamer mediates small interfering RNA delivery.A DNA dual lock-and-key strategy for cell-subtype-specific siRNA delivery.GCPII imaging and cancer.Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy Multilayer coating of gold nanorods for combined stability and biocompatibility.Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.Nucleotide bias observed with a short SELEX RNA aptamer library A status report on RNAi therapeutics.Nucleic acid aptamers: clinical applications and promising new horizons

P2860

Q26752263-94FEF983-852A-4D5F-8F24-E845ACA2B0BE Q26766832-315D3D6B-7F42-483D-ACF5-B21BA7239D6E Q26770523-6A06EB72-4E05-4704-B475-89CEF262237D Q26774462-92A65182-26C2-4EE3-BA3E-6CF192624EFB Q26778234-5AF13AE2-86C5-4917-8DE1-E1A07128EBB3 Q26782201-5496A0C5-599D-48AE-BED1-1C39F9BE0EF6 Q26849947-DF4AB699-97CA-4181-BAF6-300F95E11894 Q27025832-23C56C0D-19E5-444F-8AC4-923BABE398B5 Q27326068-BF9A7611-AF44-4C1D-82CF-C6FB60942B64 Q28066827-8B9DC80D-C2CB-402B-ACB8-1DB6DCCCF681 Q28068981-B49F043B-52EC-4F4A-B286-FCCA4ADBC221 Q28083494-152D38D0-17C1-4415-9581-16CDFF62BCD6 Q28235733-7DFB314D-17EE-4F19-8FC9-6BE5E96416C9 Q28255877-56DFF77F-0FD0-4BFC-8625-10C041938DCA Q28468281-BB389CB0-CBE3-4371-A0F8-1C50169FD346 Q28481099-E3351CD8-6286-451C-82D0-7B3E47F4409C Q28543800-034C79D0-FED6-4B3E-8055-235433E53F90 Q28727743-1F028197-A115-460D-A70A-AE8738E0DB7F Q28743866-21AF64BB-C424-446D-B025-3C456C5DFD58 Q28829750-10782F02-AB44-4261-8003-D2123873A6A0 Q28834048-E464BE86-5312-4BD7-97B0-F70C3B6B4D99 Q29039090-65E6B507-D100-4147-B106-785B90FDA890 Q30466572-7E364119-D3A4-4BBB-BEB9-1C009B5136DD Q33348480-19D14488-42C2-4F4D-A1B2-A1A59BE7AC32 Q33588273-979EC4EB-ECF2-4156-AEF7-91664379870D Q33632641-2C0E115F-F9EA-4D57-991F-6EDFE390C222 Q33717239-39C8F72A-D976-4A7C-9C37-30A9D83592E7 Q33724277-58A4E0B1-5A2A-4B4B-92A5-771FCE0617F9 Q33724285-FCA85F11-15B4-4595-B084-75DBCC88D7CE Q33733546-A9DB0713-DFE7-4919-90BD-8FA065B1E1DE Q33813408-65DF021B-64CF-45B2-9619-9BB9AE17DF00 Q33827632-9C9183DC-43C5-47B2-8372-0238D1454D3A Q33834772-BF453D8C-3A3A-4124-8DF0-0E2D3921BE74 Q33841048-2215BC74-2656-4EFC-B7D9-11713DD536D1 Q33887448-6FC6665B-3019-4914-9665-92602417DBA2 Q33893647-D4812083-871E-4965-8995-942F1C6DC9AF Q33951767-E61B5FC3-81AC-4153-902A-63F258895173 Q33972934-EDCE8B25-910A-4EEB-BB66-99D7D9EB8859 Q34013891-6D9C0D05-228B-4DB8-AA55-6936CA68D6A2 Q34028112-9AB93952-DD53-4D11-925D-8FD9A82FAEC9

P2860

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.

http://www.wikidata.org/entity/Q37469987

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Systemic administration of opt ...... ion of PSMA-expressing tumors.

@en

Systemic administration of opt ...... ion of PSMA-expressing tumors.

@nl

type

label

Systemic administration of opt ...... ion of PSMA-expressing tumors.

@en

Systemic administration of opt ...... ion of PSMA-expressing tumors.

@nl

prefLabel

Systemic administration of opt ...... ion of PSMA-expressing tumors.

@en

Systemic administration of opt ...... ion of PSMA-expressing tumors.

@nl

P1433

Q37469987-1E05A3B8-002A-4C27-B966-99B2D8C859AB

P1476

Q37469987-116594AE-61A7-4F2B-B46D-B43C9D7F9ED8

P2093

Q37469987-2F658FA9-7F80-476A-9A6D-6B30957685F1

Q37469987-7B56AE61-C2AD-4842-BC19-99DF32CBD30B

Q37469987-866C58B6-747A-45BC-AAAC-2F3186BEE3A9

Q37469987-90C24D6F-C79D-42F5-AD2D-071492309E60

Q37469987-930D1F52-B50B-4AC5-88BB-F1E3B4CCBF18

Q37469987-A40B3721-19BE-4FDD-B486-1098C2CAFEE2

Q37469987-AEF62501-62AD-43A7-886F-313F9AE58080

Q37469987-E5ED6F11-2359-46E8-B167-33995984F019

P2860

Q37469987-0235EC4D-3037-417D-9694-A0CDE55758D3

Q37469987-02A53096-0B07-4DF2-9A42-3913600B361B

Q37469987-035F22A4-F04A-4BCD-87D4-223888A50E82

Q37469987-05C6FC15-2F0C-4E67-B154-0EEF9E205F5E

Q37469987-0836F121-EF8D-4775-9CAA-C569CF259280

Q37469987-0B4559D7-3B06-4D8D-974C-0A752CF7DF2C

Q37469987-0B5AE8C5-668B-4423-B5E1-640BC3D58FB3

Q37469987-150381DD-7C84-418E-9DD3-0B2FD720FB2D

Q37469987-1AFC01EE-1486-4892-BFBD-6C5798198A36

Q37469987-27BEB8F0-6C2F-4C24-8D1E-35268319187A

P2888

Q37469987-90E81CE1-7187-4DD5-A165-439ED853BB95

P304

Q37469987-0F0FCF18-BE15-4470-B3C7-E682612E4EE9

P31

Q37469987-ABD1D49B-8388-476A-BB27-CD7734DEA4E3

P356

Q37469987-3880EA14-D427-4C66-9A39-7C05964E5D68

P433

Q37469987-B812E29D-8A26-41CB-9895-E6C687CCD04D

P478

Q37469987-F4BFE1DC-655E-447C-8A3C-21BCE03ABD33

P50

Q37469987-0028917D-6BC8-4320-A3D5-36AEEF2C9F1E

Q37469987-4414CA50-146B-438A-8C56-5F51C4CBEC70

P577

Q37469987-250B1B97-0B49-4CB4-AF23-05CFDCBED6C7

P5875

Q37469987-E105B335-AF69-4175-96A3-E8379784950C

P698

Q37469987-A33C2D4E-E020-4B75-8098-AB35F0B31EEF

P932

Q37469987-206E5CFB-36B7-48A1-916A-C1B85B8501CE

P356

P1433

Nature Biotechnology

P1476

Systemic administration of opt ...... sion of PSMA-expressing tumors

@en

P2093

Anton P McCaffrey

http://www.w3.org/2001/XMLSchema#string

Gregory S Thomas

http://www.w3.org/2001/XMLSchema#string

Justin P Dassie

http://www.w3.org/2001/XMLSchema#string

Katie R Stockdale

http://www.w3.org/2001/XMLSchema#string

Kristina W Thiel

http://www.w3.org/2001/XMLSchema#string

Paloma H Giangrande

http://www.w3.org/2001/XMLSchema#string

Ryan M Whitaker

http://www.w3.org/2001/XMLSchema#string

Xiu-Ying Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Functional polarity is introduced by Dicer processing of short substrate RNAs.

Asymmetry in the assembly of the RNAi enzyme complex

Functional siRNAs and miRNAs exhibit strand bias

Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain

Rational siRNA design for RNA interference

Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model.

RNAi therapeutics: principles, prospects and challenges.

Transvascular delivery of small interfering RNA to the central nervous system.

Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1.

P2888

P304

839-849

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT.1560

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

David Meyerholz

James O McNamara

P577

2009-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26761500

http://www.w3.org/2001/XMLSchema#string

P698

19701187

http://www.w3.org/2001/XMLSchema#string

P932

2791695

http://www.w3.org/2001/XMLSchema#string